Taking in mind that PCSK9 inhibitors have been developed for clinical usage of treatment of CV diseases, but their molecular mechanisms in atherosclerosis are not fully elucidated, our results suggest that the effects of Alirocumab and Evolocumab might be attributed not only to inhibition of PCSK9 action but also to their ability to attenuate its synthesis. Here, PCSK9 is linked to atherosclerosis.